Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)

被引：0
|
作者：
Garcia-Manero, G.
Yang, A. S.
Klimek, V.
Luger, S.
Newsome, W. M.
Berman, N.
Patterson, T.
Maroun, C.
Li, Z.
Ward, R.
Martell, R.
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Norris Cromprenhens Canc Ctr, Los Angeles, CA USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA
[5] MethylGene, Montreal, PQ, Canada
[6] Pharmion, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7062
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Ghanem, Hady Antoine
    Ravandi, Farhad
    Faderl, Stefan
    Cortes, Jorge
    Reyes, Ardes S.
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 903 - 903
  • [32] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [33] An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).
    Mattiuzzi, Gloria
    Lahoti, Amit
    Salahudeen, Abdulla
    Ravandi, Farhad
    Cortes, Jorge
    Vu, Khanh
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 419 - 420
  • [34] Antifungal Prophylaxis (AFP) for Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Undergoing Intensive Chemotherapy: An Experience with 730 Pts
    Mattiuzzi, Gloria
    Kantarjian, Hagop
    Ho, Jennifer
    Garcia-Manero, Guillermo
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 1206 - 1206
  • [35] A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)
    Palmisiano, Neil
    Jeschke, Grace
    Wilde, Lindsay
    Leiby, Benjamin E.
    Alpdogan, Onder
    Carabasi, Matthew
    Filicko-O'Hara, Joanne
    Gaballa, Sameh
    Grosso, Dolores
    Klumpp, Thomas R.
    Outschoorn, Ubaldo Martinez
    Wagner, John L.
    Carroll, Martin
    Porcu, Pierluigi
    Flomenberg, Neal
    Perl, Alexander E.
    Kasner, Margaret
    BLOOD, 2017, 130
  • [36] Intravenous voriconazole (IV-VORI) prevents invasive fungal infections (IFI) in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Mattiuzzi, GN
    Alvarado, G
    Kantarjian, HM
    Verstovsek, S
    Cabanillas, M
    Faderl, S
    Lim, JT
    Giles, F
    Beran, M
    O'Brien, S
    Estey, EH
    BLOOD, 2004, 104 (11) : 253A - 253A
  • [37] A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas
    Crump, Michael
    Andreadis, Charalambos
    Assouline, Sarit E.
    Rizzieri, David
    Copeland, Amanda
    Van Der Jagt, Richard H. C.
    Fox, Susan
    Reid, Gregory K.
    Besterman, Jeffrey M.
    Martell, Robert E.
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Phase II study of VNP40101M in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplasia (MIDS).
    Giles, FJ
    O'Brien, S
    Vey, N
    Feldman, E
    Rizzieri, D
    Khan, KD
    Bilgrami, SF
    Verhoef, G
    Mufti, G
    Johnson, B
    Karp, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 570S - 570S
  • [39] A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Ghanem, H.
    Kantarjian, H.
    Garcia-Manero, G.
    Ravandi, F.
    Faderl, S.
    Cortes, J. E.
    Reyes, A.
    O'Brien, S. M.
    Borthakur, G.
    Kadia, T. M.
    Burger, J. A.
    Konopleva, M.
    Jabbour, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Phase II Study of 5-Azacitidine and Vorinostat In Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance or Presence of Other comorbidities
    Garcia-Manero, Guillermo
    Estey, Elihu H.
    Jabbour, Elias
    Kadia, Tapan
    Estrov, Zeev
    Cortes, Jorge
    Boone, Patricia Ann
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 266 - 266
12345